Quick Search


 

Protocol Summaries: dolutegravir/abacavir/lamivudine

ViiV
Study ID
   Phase    Title Status
117172 phase 3 A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine Once Daily Compared to Atazanavir and Ritonavir Plus Tenofovir/Emtricitabine Once Daily in HIV-1 Infected Antiretroviral Therapy Naïve Women Active, not recruiting
200336 phase 3 ING200336: A Prospective, Interventional Pharmacokinetic and Safety Study of DTG/ABC/3TC in Pregnant Women Recruiting
200402 Phase 1 A Phase I, single dose, five-period crossover relative bioavailability study of a fixed-dose combination dolutegravir/abacavir/lamivudine dispersible tablet as compared to a co-dose of TIVICAY and EPZICOM in healthy subjects Completed
201147 phase 3 201147: a Phase IIIb, randomized, open-label study of the safety, efficacy, and tolerability of switching to a fixed-dose combination of abacavir/dolutegravir/ lamivudine from current antiretroviral regimen compared with continuation of the current antiretroviral regimen in HIV-1 infected adults who are virologically suppressed, The STRIIVING Study. Completed
202033 phase 4 Prospective Non-Interventional observational Study of use of Triumeq® and corresponding monitoring measures in clinical practice in Germany Recruiting
204662 Phase 1 A Phase I, Open-label, Single-dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of abacavir/dolutegravir/lamivudine fixed-dose combination tablets in Healthy Japanese Subjects Completed
204731 phase 4 An open label, multi-centre, post marketing surveillance (PMS) to monitor the safety and effectiveness of TRIUMEQ administered in Korean subjects for treatment of HIV-1 infection in real life practice Recruiting
205824 Phase 4 A retrospective clinical audit of high case load General Practices in Australia with patients switched to Triumeq to determine the motivation for switch and clinical outcomes after the switch Completed